<DOC>
	<DOC>NCT00522379</DOC>
	<brief_summary>The purpose of this study is to show Rotigotine dose response at four doses of Rotigotine used with L-dopa in treating advanced stage Parkinson's disease.</brief_summary>
	<brief_title>Trial to Assess Parkinson's Disease (PD) Symptom Control to Four Doses of Rotigotine in a Transdermal Patch</brief_title>
	<detailed_description>To maintain treatment blind, two different active patch sizes were used (10 cm^2 &amp; 20 cm^2). Placebo patches matched according to size and appearance. During the trial subjects applied up to three patches, active and placebo, to achieve their assigned daily dose.</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>N 0437</mesh_term>
	<criteria>PD greater than 3 years Stable dose Ldopa but symptoms not adequately controlled and have "off" time Able and willing to complete diary on specific days Previous use of rotigotine or Neupro Atypical Parkinson's syndrome Pallidotomy Thalamotomy Deep brain stimulation Fetal tissue transplant Dementia Psychosis Hallucinations Epilepsy Renal or hepatic dysfunction Clinically relevant cardiac dysfunction Symptomatic orthostatic hypotension Skin sensitivity to adhesives or unresolved contact dermatitis History of chronic alcohol or drug abuse Pregnant or of childbearing potential Impulse control disorder</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Parkinson's disease</keyword>
	<keyword>rotigotine</keyword>
	<keyword>patch</keyword>
	<keyword>transdermal</keyword>
	<keyword>dopamine agonist</keyword>
	<keyword>off time</keyword>
	<keyword>Neupro</keyword>
</DOC>